Key result
Anticoagulation during pregnancy and breast-feeding requires careful management due to maternal-fetal risks and limited data.
This review outlines the indications, challenges, and recommendations for anticoagulant use in pregnant and breast-feeding women, noting the lack of high-quality clinical trials in this population.
Answers are grounded in this paper and cite their sources.
Urges individualized peripartum anticoagulant decisions; leaves open major evidence gaps for dedicated RCTs.
Anticoagulants are indicated during pregnancy for the prevention and treatment of venous thromboembolism (VTE), in patients with mechanical heart valves, as well as for the prevention of pregnancy loss in women with antiphospholipid antibodies (APLA). Anticoagulant therapy is also increasingly being employed for prevention of pregnancy complications in women with hereditary thrombophilia. Anticoagulant use during pregnancy is challenging because of the potential for fetal, as well as maternal, complications and because there is a paucity of high-quality clinical trials in this patient population upon which to make management decisions. This chapter will review the use of anticoagulants during pregnancy and in breast-feeding women and provide recommendations for the treatment and prevention of VTE, anticoagulant management in women with prosthetic mechanical valves, and prevention of pregnancy complications in women with thrombophilias.
No takes yet. Share an insight, caveat, or question.
Shannon M. Bates (2016) conducted a review in Pregnancy requiring anticoagulation. Anticoagulants was evaluated. Anticoagulant use during pregnancy and breast-feeding requires careful management due to potential fetal and maternal complications and a lack of high-quality clinical trials.
Synapse has enriched 10 related papers. Consider them for comparative context: